Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $20.57

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $20.57.

Several research analysts have recently commented on STOK shares. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, May 7th. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. raised their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, March 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Monday, May 6th. Finally, Canaccord Genuity Group reduced their target price on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $12.92 on Thursday. The firm has a market cap of $673.40 million, a PE ratio of -5.36 and a beta of 0.88. The company has a 50-day moving average of $13.73 and a two-hundred day moving average of $9.27. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.03. The business had revenue of $4.22 million during the quarter, compared to analysts’ expectations of $3.33 million. Sell-side analysts anticipate that Stoke Therapeutics will post -2.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 11.30% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Birchview Capital LP increased its holdings in shares of Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after acquiring an additional 125,000 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Stoke Therapeutics by 514.7% in the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after acquiring an additional 291,443 shares during the period. Trexquant Investment LP increased its holdings in shares of Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares during the period. Corton Capital Inc. acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $58,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $64,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.